

# Pharmaceutical Benefits Scheme (PBS) Listings

## 1 January 2026

Please find below information relating to new and amended Pharmaceutical Benefits Scheme (PBS) listings implemented on **1 January 2026**.

This information relates to the administration of these listings by Services Australia. For further information on broader PBS changes, please visit the PBS website. Relevant information and authority application forms have been updated and can be accessed through the Services Australia website.

### **Progressive familial intrahepatic cholestasis (PFIC)**

Odevixibat (200 mcg capsule; 400 mcg capsule; 600 mcg capsule; 1.2 mg capsule) (Bylvay®) is now listed on the PBS for the treatment of PFIC. Authority applications for initial treatment can be made using the Online PBS Authorities system or in writing. Applications for dose modification and continuing treatments can be made using the Online PBS Authorities system or by telephone.

### **Enthesitis/spondylitis related juvenile idiopathic arthritis & Severe active juvenile idiopathic arthritis**

Adalimumab (20 mg/0.2 mL injection, 2 x 0.2 mL syringes; 20 mg/0.4 mL injection, 0.4 mL syringe; 20 mg/0.4 mL injection, 2 x 0.4 mL syringes; 40 mg/0.4 mL injection, 2 x 0.4 mL pen devices; 40 mg/0.4 mL injection, 2 x 0.4 mL syringes; 40 mg/0.8 mL injection, 2 x 0.8 mL pen devices; 40 mg/0.8 mL injection, 2 x 0.8 mL syringes) is now listed on the PBS for the treatment of enthesitis/spondylitis related juvenile idiopathic arthritis. For paediatric patients with Severe active juvenile idiopathic arthritis there has been a change to the restrictions. Authority applications for initial and grandfather treatments can be made using the Online PBS Authorities system or by telephone. Prescriptions for continuing treatment are Authority required (STREAMLINED).

### **Severe established osteoporosis**

Teriparatide (250 microgram/mL injection, 2.4 mL pen device) (Ritosa®) is now listed on the PBS for the treatment of severe established osteoporosis. Prescriptions for initial and continuing treatments are Authority required (STREAMLINED).

### **Multiple sclerosis**

Ublituximab (150 mg/6 mL injection, 6 mL vial) (Briumvi®) is now listed on the PBS for the treatment of multiple sclerosis. Prescriptions for initial and continuing treatments are Authority required (STREAMLINED).

### **Moderate to severe ulcerative colitis & complex refractory Fistulising Crohn's disease**

Ustekinumab (90 mg/mL injection, 1 mL syringe) (Steqeyma®) for the treatment of moderate to severe ulcerative colitis & complex refractory Fistulising Crohn's disease has had a change to the listing for subsequent continuing treatment. The number of listed repeats has been increased from 1 to 2. Prescriptions for subsequent continuing treatment are Authority required (STREAMLINED).

### **Dermatitis herpetiformis; leprosy; actinomycotic mycetoma**

Dapsone (50 mg tablet) (Dapsomed®) is now listed on the PBS as an unrestricted benefit.

## **1 January 2026 delisted PBS listings**

### **HIV infection**

Atazanavir (200 mg capsule; 300 mg capsule)(Reyataz®) has been delisted with a supply only arrangement for 6 months.

### **Chronic open angle glaucoma; ocular hypertension**

Brimonidine (brimonidine tartrate 0.15% eye drops, 5 mL)(Alphagan P 1.5®) has been delisted with a supply only arrangement for 5 months.

## **PBS Authorities – Changes from 1 January 2026**

We understand having access to PBS-subsidised medicines can be critical to patient care. That's why Services Australia and the Department of Health, Disability and Ageing are continuing to work together to increase the number of PBS medicines that can be requested and approved using the Online PBS Authorities system (the system).

From 1 January 2026, you will be able to use the system to apply for authority approval and provide evidence digitally for the following medicines. These changes will make it easier for you to request authority approval for these medicines from Services Australia. You will no longer need to submit the written authority application form, details of the proposed prescriptions and test results for certain medicines and treatment phases.

### **Treatment of moderate to severe chronic pouchitis**

Authority applications for initial and recommencement treatments can now be made using the Online PBS Authorities system or in writing. Applications for continuing treatment can be made using the Online PBS Authorities system or by telephone.

## **Important Information**

### **Uncontrolled severe asthma - dupilumab**

Following a review of Services Australia's administration of the Pharmaceutical Benefits Scheme (PBS), prescribers cannot swap patients between dupilumab 200 mg and 300 mg strengths for the treatment of uncontrolled severe asthma. This is because the respective strengths are PBS approved for different patient cohorts. When demonstrating patient eligibility for dupilumab, prescribers will be required to confirm that their patient is not changing strengths. Eligibility Q&As and application forms have been updated.

### **Submitting Pharmaceutical Benefits Scheme (PBS) Written Applications through Health Professional Online Services (HPOS) form upload**

When submitting PBS authority forms through HPOS form upload, it is important to select the correct Form Category. For PBS patients, select PBS Authorities. For DVA patients, select RPBS Authorities. Remember that only yourself or your delegate/s are authorised to upload PBS and RPBS Authority applications.

Make sure you've:

- linked your prescriber number to your Provider Digital Access (PRODA) account for HPOS; and
- Set up your delegations in HPOS.

Visit [servicesaustralia.gov.au/HPOS](https://servicesaustralia.gov.au/HPOS) for more information on how to Link your Health Identifiers to HPOS and Manage delegations.

### **PBS Authorities items criteria**

Under the PBS, medicines are made available based on recommendations from the Pharmaceutical Benefits Advisory Committee (PBAC). Patients must meet the set criteria to be eligible for PBS subsidised medicines. Services Australia are unable to provide approval for an Authority Required medication where a patient does not meet the criteria established by PBAC.

If you have concerns or questions about the eligibility criteria set by PBAC, you can contact the Department of Health, Disability and Ageing by email at [pbs@health.gov.au](mailto:pbs@health.gov.au).

### **Reminders**

#### **PBS Authorities – written authority application forms**

To align with PBS listing changes, forms are updated on the first of the month. Using the most recent form will help avoid delays in obtaining authority approval. Search the Services Australia website to access the most recent forms.

#### **Correct PBS item code**

When prescribing PBS medicines via the Online PBS Authorities system, ensure you have selected the correct medicine to match what is on the prescription. This will avoid delays with providing patients with the medication they require.

#### **Ensuring you are providing accurate data**

It's important to ensure you are providing accurate and up to date information when completing an authority application. Failure to do so may result in your authority request being rejected.

### **More information**

For more information about the Online PBS Authorities system visit [www.servicesaustralia.gov.au/hppbsauthorities](http://www.servicesaustralia.gov.au/hppbsauthorities)

Services Australia has a broad range of educational resources on the Health Professional Education Resources website. This includes simulations, podcast and an infographic on the Online PBS Authorities system. Visit <https://hpe.servicesaustralia.gov.au/pharmaceutical-benefits-scheme.html>

Visit [servicesaustralia.gov.au/hpwrittenauthoritydrugs](http://servicesaustralia.gov.au/hpwrittenauthoritydrugs) on the Services Australia website to find the most up to date authority application form for each drug, program or condition.